Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a targeted agent and immunotherapy were...
Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a targeted agent and immunotherapy were...
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have...
Liver cancer patient Ron Clement was able to quickly get back to favorite hobbies, including birdwatching, after undergoing a type...